GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioAtla Inc (NAS:BCAB) » Definitions » Debt-to-EBITDA

BioAtla (BioAtla) Debt-to-EBITDA : -0.02 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioAtla Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioAtla's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.62 Mil. BioAtla's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.84 Mil. BioAtla's annualized EBITDA for the quarter that ended in Dec. 2023 was $-112.67 Mil. BioAtla's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioAtla's Debt-to-EBITDA or its related term are showing as below:

BCAB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.66   Med: -0.05   Max: -0.02
Current: -0.02

During the past 6 years, the highest Debt-to-EBITDA Ratio of BioAtla was -0.02. The lowest was -0.66. And the median was -0.05.

BCAB's Debt-to-EBITDA is ranked worse than
100% of 274 companies
in the Biotechnology industry
Industry Median: 1.325 vs BCAB: -0.02

BioAtla Debt-to-EBITDA Historical Data

The historical data trend for BioAtla's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioAtla Debt-to-EBITDA Chart

BioAtla Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.66 -0.02 -0.06 -0.04 -0.02

BioAtla Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.03 -0.02 -0.02 -0.02

Competitive Comparison of BioAtla's Debt-to-EBITDA

For the Biotechnology subindustry, BioAtla's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioAtla's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioAtla's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioAtla's Debt-to-EBITDA falls into.



BioAtla Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioAtla's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.624 + 0.836) / -128.466
=-0.02

BioAtla's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.624 + 0.836) / -112.672
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioAtla  (NAS:BCAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioAtla Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioAtla's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioAtla (BioAtla) Business Description

Traded in Other Exchanges
N/A
Address
11085 Torreyana Road, San Diego, CA, USA, 92121
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise Mecbotamab vedotin, Ozuriftabmab vedotin, BA3071, and Bispecific antibody programs.
Executives
Sylvia Mcbrinn director
Short Jay M Phd director, 10 percent owner, officer: Chief Executive Officer C/O DIVERSA CORPORATION, 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Christian Vasquez officer: See Remarks 121 E. PALOMAR STREET, CHULA VISTA CA 91911
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Eddie Williams director 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Scott Andrew Smith director, officer: President C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Eric Sievers officer: Chief Medical Officer 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Richard A Waldron officer: Chief Financial Officer 901 MARINERS ISLAND BLVD STE.205, SAN MATEO CA 94404
Guy Levy director, 10 percent owner C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Soleus Pe Gp I, Llc 10 percent owner 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Himalaya Parent Llc 10 percent owner 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Susan Moran director 1232 RICHARDSON AVE, LOS ALTOS CA 94024
Carolyn Anderson Short 10 percent owner, officer: See Remarks 11085 TORREYANA ROAD, SAN DIEGO CA 92121
Priyanka Belawat director C/O ITEOS THERAPEUTICS, INC., 139 MAIN STREET, CAMBRIDGE MA 02142